Doryx is an antibiotic owned by Mayne Pharma. Its active ingredient is doxycycline hyclate and it first came to market on May 6, 2005.
The last patent for Doryx is set to expire on December 23, 2034, which is when a generic version of the drug could potentially be released, barring any successful Para IV filings that might bring it to market sooner.
Doryx is utilized to treat or prevent infections caused by susceptible bacteria. It is specially designed as a delayed-release tablet consisting of doxycycline hyclate coated pellets.
Doryx has a total of 5 drug patents of which only one has expired. The last Doryx generic patent will expire on December 23, 2034. Below are the details of the patent: